NCT00739661View on ClinicalTrials.gov

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission

PHASE2CompletedINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Ovarian Cancer

Interventions

DRUG

Vismodegib 150 mg

Vismodegib 150 mg was provided in hard gelatin capsules.

DRUG

Placebo to vismodegib

Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.